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Abstract 
The hepatitis C virus (HCV) NS5B protein is known essential for virus 
replication and suggested play important role in therapy resistance mechanism. 
To predict and more understanding the molecular pattern of HCV 1a NS5B we 
cloned the NS5B gene of HCV 1a isolated in Central of Java Indonesia using stan-
dard cloning procedure. The sequence results were then aligned with all of HCV 
1a NS5B complete coding sequences reported in GenBank. In total, 397 se-
quences were retrieved and aligned by ClustalW. We revealed the amino acid se-
quence consensus of HCV NS5A gene. Overall, variations were found at aa 5, 11, 
15, 33, 36, 37, 46, 47, 50, 55, 57, 59, 62, 63, 65, 66, 68, 71, 73, 77, 81, 82, 84-86, 
90, 98, 101, 110, 113, 116, 117, 120, 124, 130, 134, 135, 144, 147-149, 151, 
156, 162, 166, 173, 177-180, 184, 189, 198, 202, 206, 207, 209, 210, 212, 213, 
231, 235, 238, 248, 251, 252, 254, 262, 267, 270, 273, 300, 307, 309, 310, 327, 
330, 333, 334, 355, 374, 376, 377, 379, 389, 392, 400, 401, 402, 405, 412, 415, 
421, 423-427, 431, 432, 434, 435, 437, 440, 451, 452, 454, 455, 459, 461, 464, 
480, 487, 499, 506, 510, 512, 513,517, 520, 523, 531, 535, 540, 543, 544, 549, 
552, 556, 564-566, 572, 574, 580, 581, 585, and 588. Amino acid variations may 
have relevant changes of physicochemical properties so that influence the repli-
cation efficiency, therefore, the amino acid variations found in the present re-
port need further study. 
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INTRODUCTION 
 
Hepatitis C virus (HCV) is a positive-
strand RNA virus that frequently causes 
persistent infections. Chronic infection by 
hepatitis C virus (HCV) can lead to severe 
hepatitis and cirrhosis and is closely 
associated with hepatocellular carcinoma. The 
HCV nonstructural protein 5B (NS5B) forms a 
complex with the retinoblastoma tumor 
suppressor protein (pRb), targeting it for 
degradation, activating E2F-responsive 
promoters, and stimulating cellular 
proliferation. The disruption of pRb/E2F 
regulatory pathways in cells infected with HCV 
is likely to promote hepatocellular 
proliferation and chromosomal instability, 
factors important for the development of liver 
cancer (1). HCV-induced cytopathogenicity is 
associated with the level of intracellular viral 
replication and is determined by certain 
amino acid substitutions in HCV- NS5B regions  
(2).  
 
The replication cycle of HCV is likely to 
involve interaction with host factors (3). HCV 
replicates its genome in replication complexes 
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(RC) associated to endoplasmic reticulum 
(ER)-derived micro-vesicles. One key protein 
in these complexes is NS5B, HCV enzyme that 
shows the RNA binding and RNA-dependent 
RNA polymerase (RdRp) activities. The HCV 
NS5B RNA polymerase facilitates the RNA 
synthesis step during the HCV replication 
cycle. Nucleoside analogs targeting the NS5B 
provide an attractive approach to treating HCV 
infections because of their high barrier to 
resistance and pan-genotype activity. For this 
reason, NS5B protein has become one of the 
most important targets for designing new 
antiviral therapy compounds (4, 5). To predict 
and more understanding the molecular pattern 
of HCV NS5B gene, we cloned the HCV NS5B 
gene from HCV 1a isolated in Central of Java 
Indonesia and performed bioinformatics study 
of all HCV 1a NS5B complete genes deposited 
in GenBank. Here we present our current 
analysis results of the NS5B gene of HCV 1a. 
 
 
MATERIALS AND METHODS 
 
Isolate Selection for Cloning 
 
Previously, all plasma aliquot with anti-
HCV positive from previous study (Prasetyo, et 
al., submitted for publication) were performed 
for nucleic acid extraction followed with 
nested RT-PCR addressed part of the HCV E1-
E2 and HCV NS5B region. The positive PCR 
products were sequenced and phylogenetic 
analyzed to role out the predominant HCV in 
Central of Java Indonesia. All samples having 
the same genotype with the predominant 
genotype were further analyzed for its co-
infection with another human blood borne 
viruses (HIV, HBV, HDV, HTLV-1/2, and TTV), 
HCV RNA titer, and sequencing results. 
 
Cloning of HCV 1a NS5B Gene from HCV 1a 
Isolated in Central of Java Indonesia 
 
The aliquot plasma from “the best 
candidate for cloning”-isolate were performed 
for RNA extraction followed with cDNA 
synthesis. The HCV 1a NS5B gene was cloned 
using HCV 1a NS5B-F: 5'-ATG TCR ATG TCY 
TAY WCY TGG ACA GGC-3' and HCV 1a NS5B-
R: 5'-TTA TCG RTT GGG RHR GAG RTA RAT 
RCC TAC C-3' primers. The PCR cloning was 
performed using Accuprime Pfx Polymerase 
(Invitrogen, Carlsbad, CA) according its 
protocol. The PCR conditions for cloning was 
performed with early denaturation for 2 
minutes of 95 °C, 16 cycles of 95 °C 15 seconds 
of denaturation followed with 55 °C 30 
seconds of annealing and 68 °C 1 minute of 
elongation, respectively. The final elongation 
period was 72 °C 10 minutes. The PCR 
products were purified, analyzed, and 
subcloned into pETBlue-1 (Novagen, 
Darmstadt, Germany). The recombinant 
plasmids were then transformed into 
competent cells. The competent cells were 
propagated, harvested, and the plasmids were 
extracted and sequenced. The sequencing 
results were analyzed using CLC Sequence 
Viewer 6 and MEGA4. 
 
Complete HCV 1a NS5B Gene Sequences 
 
First, all HCV 1a NS5B gene sequences 
deposited in GenBank were downloaded. In 
total, 397 sequences with complete coding se-
quence were retrieved from GenBank. The se-
quences then were aligned by ClustalW, for 
both of nucleotide and amino acid sequences, 
using CLC Sequence Viewer 6 and MEGA4. 
From this alignment we revealed the amino 
acid consensus sequences. The tested se-
quences were aligned by ClustalW with subse-
quent inspection and manual modification. 
 
 
RESULTS AND DISCUSSION 
 
Prior of cloning the NS5B gene of HCV 1a, 
we performed phylogenetic analysis of all HCV 
isolated in Central of Java Indonesia from the 
previous study. In total, 140 out of 518 plasma 
samples were positive for anti-HCV. From all 
positive plasma samples, 32 isolates were 
successfully amplified with nested RT-PCR 
addressed for part of HCV E1-E2 and HCV 
NS5B region. The phylogenetic analysis 
retrieved that 43.72% (14/32) isolates were 
HCV 1a (Prasetyo, et al., submitted for 
publication). 
 
To find the best isolate for cloning, all 
HCV 1a isolates were further analyzed. After 
checked the co-infection status with other 
human blood borne viruses, measured the 
quantity of the HCV RNA, and based on the 
prior HCV E1-E2 and HCV NS5B sequencing 
Journal of Biotechnology and Biodiversity, April 2011; 2: 10-18 
ISSN: 2087-0183 
  
12 
 
results, 09IDSKAC-20 was chosen for cloning. 
The HCV 1a NS5B gene was cloned from 
09IDSKAC-20 RNA using standard cloning 
procedure. Briefly, to design the primers for 
cloning, we performed alignment of all 
complete open reading frames for HCV 1a 
NS5B gene. The motif sequences of the 5’end 
and the 3’end regions were retrieved and 
subjected for primer design using FastPCR 
software. The initiation and stop codon were 
added into the forward and backward primer, 
respectively, to ensure the expression of HCV 
1a NS5B in the pETBlue-1 plasmid. The PCR 
products was then subcloned into pETBlue-1, 
and transformed into competent cells. The 
recombinant plasmids were extracted and 
sequenced. The sequences were aligned with 
all HCV 1a NS5B genes retrieved from 
GenBank. 
 
Different hepatitis C virus (HCV) proteins 
have been associated with different response 
to therapy, including that of the drugs 
resistance. However, the exact mechanisms of 
virus-mediated resistance are not completely 
understood. The importance of amino acid 
(aa) variations within the HCV 1a NS5B 
proteins for replication efficiency and viral 
decline during the therapy is unknown. To 
solve this problem we performed 
bioinformatics study by analyzing the all of 
HCV 1a NS5B gene complete coding sequences 
deposited in GenBank. 
 
The molecular pattern of HCV 1a NS5B 
was found as follows:  
1SMSYT/SWTGAL10 
11I/VTPCA/V/T/SAEEQK20 
21LPINALSNSL30 31LRH/NHNL/MV/IYST40 
41TSRSAS/CQ/L/HRQK/R50 
51KVTFD/ERL/M/Q/VQV/IL60 
61DS/N/DH/YYQ/RD/E/GVL/VKE70 
71V/IKA/T/VAASK/R/TVKA80 
81N/K/S/DL/MLS/TV/IE/DEACS/D90 
91LTPPHSAK/RSK100 
101F/YGYGAKDVRC/S110 
111HAR/KKAV/IN/A/T/SHIN/R/S120 
121SVWK/E/A/Q/NDLLEDS/N130 
131VTPI/L/MD/NTTIMA140 
141KNEV/IFCV/IQ/E/AP/AE150 
151K/RGGRKP/A/SARLI160 
161VF/YPDLG/SVRVC170 
171EKM/RALYD/QV/LV/IS/K/R/T/N/G180 
181KLPL/Q/V/P/T/I/MAVMGS/A/K/G/DS19
0  
191YGFQYSPG/A/R/KQR200 
201VE/DFLVQ/R/KA/TWK/S/NS/A/R/H210 
211KR/K/GT/V/A/N/SPMGFSYD220 
221TRCFDSTVTE230 
231S/N/G/HDIRT/MEEA/T/EIY240 
241QCCDLDPQ/EAR250 
251V/I/MA/VIK/RSLTERL260 
261YV/IGGPLT/INSR/K270 
271GEN/SCGYRRCR280 281ASGVLTTSCG290 
291NTLTCYIKAR/Q/K300 
301AACRAAG/RLQ/RD/N/S/A310 
311CTMLVCGDDL320 
321VVICESA/Q/E/VGVQ/P/R330 
331EDA/VAS/N/A/C/R/GLRAFT340 
341EAMTRYSAPP350 
351GDPPQ/R/HPEYDL360 
361ELITSCSSNV370 
371SVAH/QDG/D/S/NA/T/D/NGK/RR380 
381VYYLTRDPT/AT390 
391PL/FARAAWETA/S/V400 
401R/KH/RTPV/INSWLG410 
411NI/VIMF/YAPTLW420 
421A/VRM/I/VI/VL/MM/LT/PHFF430 
431S/GV/ILI/M/LA/TRD/EQLE/D440  
441 QALDCEIYGA450  
451 C/H/YY/HSI/VE/Q/KPLDL/IP460  
461 P/L/Q/SIIQ/ERLHGLS470  
471AFSLHSYSPG/S480 
481EINRVAA/TCLR490 
491KLGVPPLRA/TW500 
501RHRARN/S/T/GVRAR/K510 
511LL/MS/ARGGR/K/GAAI/T/V/M520 
521CGK/RYLFNWAV530 
531R/KTKLK/RLTPIA/P540 
541AAG/S/D/NQ/RLDLSG/SW550 
551FT/K/RAGYS/GGGDI560 
561YHSV/MS/PR/HARPR570 
571WF/L/I/YWF/ICLLLLA/T/G580 
581A/TGVGI/VYLL/F/YPN R591  
 
Variations were found at aa 5, 11, 15, 33, 
36, 37, 46, 47, 50, 55, 57, 59, 62, 63, 65, 66, 68, 
71, 73, 77, 81, 82, 84-86, 90, 98, 101, 110, 113, 
116, 117, 120, 124, 130, 134, 135, 144, 147-
149, 151, 156, 162, 166, 173, 177-180, 184, 
189, 198, 202, 206, 207, 209, 210, 212, 213, 
231, 235, 238, 248, 251, 252, 254, 262, 267, 
270, 273, 300, 307, 309, 310, 327, 330, 333, 
334, 355, 374, 376, 377, 379, 389, 392, 400, 
401, 402, 405, 412, 415, 421, 423-427, 431, 
432, 434, 435, 437, 440, 451, 452, 454, 455, 
459, 461, 464, 480, 487, 499, 506, 510, 512, 
513,517, 520, 523, 531, 535, 540, 543, 544, 
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549, 552, 556, 564-566, 572, 574, 580, 581, 
585, and 588. 
 
 
DISCUSSION 
 
The hepatitis C virus (HCV) encodes an 
RNA-dependent RNA polymerase (NS5B), 
which is indispensable for the viral genome 
replication. NS5B is a tail-anchored protein 
with a highly conserved C-terminal 
transmembrane domain (TMD) that is 
required for the assembly of a functional 
replication complex (6). Different structural 
elements of NS5B have been reported to 
participate in RNA synthesis, especially a so-
called "β-flap" and a C-terminal segment 
(designated "linker") that connects the 
catalytic core of NS5B to a transmembrane 
anchor. The transition from the first 
dinucleotide primer state to processive RNA 
synthesis requires removal of the linker and of 
the β-flap with which it is shown to strongly 
interact in crystal structures of HCV NS5B (7). 
Replication of the plus-stranded RNA genome 
of HCV occurs in a membrane-bound 
replication complex consisting of viral and 
cellular proteins and viral RNA. NS5B is 
anchored to the membranes via a C-terminal 
20-amino-acid-long hydrophobic domain, 
which is flanked on each side by a highly 
conserved positively charged arginine. 
Anchoring NS5B to membranes is necessary 
but that the amino acid sequence of the anchor 
per se does not require HCV origin. This 
suggests that specific interactions between the 
NS5B hydrophobic domain and other 
membrane-bound factors may not play a 
decisive role in HCV replication (8). 
 
The 249-nt-long RNA segment in the C-
terminal NS5B coding region (NS5BCR) is 
predicted to form four stable stem-loop 
structures (SL-IV to SL-VII). Two of the stem-
loops (SL-V and SL-VI) are essential for 
replication of the HCV. Mutations in the loop 
and the top of the stem of these RNA elements 
abolished replicon RNA synthesis but had no 
effect on translation (9).  
 
The crystal structure of HCV NS5B 
highlights the presence of a unique A1-loop, 
which extends from the fingers to the thumb 
domain (amino acids 12-46), providing many 
contact points for the proposed "closed" 
conformation of the enzyme. The polymerase 
also possesses a tunnel, which starts at the 
active site and terminates on the back surface 
of the enzyme. The replacement of leucine 30 
located in the Lambda 1-loop is detrimental to 
the NS5B activity. Amino acid substitutions in 
Arg-222 and Lys-151 within the putative NTP 
tunnel indicates that Arg-222 was critical in 
delivering NTPs to the active site, whereas 
Lys-151 was dispensable (10). The leucine-20 
and arginine-222 were completely conserved; 
however, lysine 151 was not completely 
conserved in HCV 1a NS5B indicates that this 
residue is not essential for NS5B activity. 
 
Several consensus sequence motifs have 
been identified in NS5B. A unique beta-hairpin 
structure located between amino acids 443 
and 454 in the thumb subdomain has also 
been shown to play an important role in 
ensuring terminal initiation of RNA synthesis 
in vitro. Furthermore, a conservative 
substitution in motif D, from an arginine 
residue (AMTR(345)), which is conserved 
among all HCV isolates, to a lysine residue, 
resulted in significant improvements in both 
transient RNA replication and colony 
formation efficiencies (11). Interestingly, amino 
acid variations were found in 451, 452, and 
454. These variations role in RNA synthesis 
needs further study. Mutations on Q377R, 
A450S, S455N, R517K, and Y561F in the NS5B 
region resulted in up-regulation of NS5B 
polymerase activity in vitro (12). However, aa 
377, 455, and 517 have variations in HCV 1a. 
Amino acids 220 and 288, were critical, and 
amino acids 213 and 231, were important for 
efficient HCV replication (13). The aa 220 and 
288 were fully conserved in HCV 1a while 213 
and 231 were not. 
 
Hepatitis C virus (HCV) replication and 
infection depend on the lipid components of 
the cell, and replication is inhibited by 
inhibitors of sphingomyelin biosynthesis. The 
sphingomyelin binding domain (SBD) of HCV 
NS5B was mapped to the helix-turn-helix 
structure (residues 231 to 260), which was 
essential for sphingomyelin binding and 
activation. Helix structures (residues 231 to 
241 and 247 to 260) are important for NS5B 
activation, and 238S and 248E are important 
for maintaining the helix structures for 
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template binding and NS5B activation by 
sphingomyelin. 241Q in helix 1 and the 
negatively charged 244D at the apex of the 
turn are important for sphingomyelin binding 
(14). These data were consistent with the 
alignment results since 241Q and 244D were 
conserved in HCV 1a NS5B. However, 
variations were found in amino acid 238 and 
248.  
 
It has been suggested that cellular 
proteins are involved in hepatitis C virus 
(HCV) RNA replication. Domains NS5B (84-
95), NS5B (466-478), and alpha-actinin (621-
733) are responsible for the interaction (15). 
However, variations were found at aa 84-86, 
and 90 indicate that domains NS5B (84-95) 
maybe not essential for the interaction 
especially for that of genotype 1a. No amino 
acid variation was found in domains NS5B 
(466-478). 
 
Hepatitis C Virus (HCV) non-structural 
proteins are major components of replication 
complex that is modulated by several host 
factors. Nucleolin, a representative nucleolar 
marker, interacts with the NS5B through two 
separated sequences, amino acids (aa) 208-
214 and 500-506, and that W208 in the 
former stretch is essential for both nucleolin-
binding and HCV replication (16). Arginine-
glycine-glycine (RGG) repeat in the Glycine 
arginine rich (GAR) domain were defined to be 
indispensable for NS5B-binding (17). However, 
amino acid variations were found at aa 209, 
210, 212, 213, and 506 of NS5B HCV 1a. W208 
was fully conserved in HCV 1a. 
 
The hepatitis C virus (HCV) NS5B RNA-
dependent RNA polymerase (RdRp) plays a 
central role in virus replication. NS5B has no 
functional equivalent in mammalian cells and, 
as a consequence, is an attractive target for 
inhibition (18). siRNAs targeting against HCV 
NS5B efficiently inhibit HCV replication (19). 
Nucleoside analogs targeting the NS5B 
provide an attractive approach to treating HCV 
infections because of their high barrier to 
resistance and pan-genotype activity. 
Ribavirin (RBV), a nucleoside analogue, is 
used in the treatment of hepatitis C virus 
(HCV) infection in combination with 
interferons. Y2471H in NS5B region plays a 
role in the reduced susceptibility to RBV and 
leads to decrease in replication fitness of 
genotype 2a (20). Mutation in Ser272Pro, 
Met312Thr, and Arg221Lys correlated with 
end-of-treatment response but relapsed, failed 
treatment after 3 months due to anemia, and 
end-of-treatment-response but relapsed 
conditions, respectively (21). NS5B F415Y 
mutation represents an RBV-resistant variant 
(22). PSI-7851 is a highly active nucleotide 
analog inhibitor of HCV but less active against 
the S282T mutant  (5). The nucleotide analogue 
2'-C-methyl CTP (2'-C-Me-CTP) is the active 
metabolite of NM283, a drug currently in 
clinical phase II trials. Resistance to 2'-C-
Methyl-Cytidine was mapped to amino acid 
substitution S282T in the NS5B coding region 
(23, 24, 25). 
 
Multiple nonnucleoside inhibitor binding 
sites have been identified within the hepatitis 
C virus (HCV) polymerase, including in the 
palm and thumb domains. Hepatitis C virus 
(HCV) non-nucleoside inhibitors (NNIs) target 
the viral RNA-dependent RNA polymerase 
encoded by the NS5B gene. Several NNIs share 
a similar allosteric binding site, and their 
antiviral efficacy is attenuated by a cysteine-
to-tyrosine mutation at amino acid 316 
(C316Y) (26). HCV-796 is a nonnucleoside 
inhibitor of the HCV NS5B polymerase. 
Mutations known to confer resistance to HCV-
796 (NS5B C316Y) was present in the 
resistant replicons (27). Mutations were 
observed at Leu314, Cys316, Ile363, Ser365, 
and Met414 of NS5B, which directly interact 
with HCV-796. Reduced binding affinity with 
HCV-796 was demonstrated in an enzyme 
harboring the C316Y mutation (28).  
 
Compounds A-782759 (an N-1-aza-4-
hydroxyquinolone benzothiadiazine) is 
specific inhibit the HCV NS5B. Single 
substitutions in the NS5B polymerase gene 
(H95Q, N411S, M414L, M414T, or Y448H) 
resulted in substantial decreases in 
susceptibility to A-782759 (29). A-837093 is a 
potent and specific nonnucleoside inhibitor of 
the HCV NS5B. It also exhibited an excellent 
metabolic profile and achieved high plasma 
and liver concentrations in animals. Several 
mutations were associated with resistance to 
A-837093, including S368A, Y448H, G554D, 
D559G, C316Y, G554D, Y555C, and D559G (30, 
31). Thiophene-based non-nucleoside 
Cloning and Molecular Virus 1a NS5B                                                                                                                                Prasetyo, A. A. 
15 
 
inhibitors (NNIs) bound non-covalently to 
NS5B. It has been reported that Pro495, 
Pro496, Val499 and Arg503 are part of the 
guanosine triphosphate (GTP) specific 
allosteric binding site (32). After a single 
treatment with a thumb site inhibitor 
(thiophene-2-carboxylic acid NNI-1), resistant 
HCV replicon variants emerged that contained 
mutations at residues Leu419, Met423, and 
Ile482 in the polymerase thumb domain. The 
mechanism of resistance is through the 
reduced binding of the inhibitor to the mutant 
enzymes (33).  
 
Isothiazole analogs were discovered as a 
novel class of active-site inhibitors of HCV 
NS5B polymerase, covalently linked with Cys 
366 of the 'primer-grip' (34). A series of 
benzimidazole 5-carboxamide compounds 
inhibit the cellular RNA replication of a HCV 
subgenomic replicon. A binding site has been 
localized for these inhibitors at the junction of 
the thumb domain and the N-terminal finger 
loop. Resistant mutations that emerged with 
the benzimidazole 5-carboxamide and related 
compounds were found at three amino acid 
positions in the thumb domain: Pro(495) with 
substitutions to Ser, Leu, Ala, or Thr; Pro(496) 
substitutions to Ser or Ala; and a V499A 
substitution (35).  
 
Pyranoindoles target the NS5B 
polymerase through interactions at the thumb 
domain. This inhibition is independent of GTP 
concentrations and is likely mediated by an 
allosteric blockade introduced by the inhibitor 
during the transition to RNA elongation after 
the formation of an initiation complex. 
Mutations in the NS5B polymerase gene 
corresponding to the drug-binding pocket on 
the surface of the thumb domain identified by 
X-ray crystallography. An additional cluster of 
mutations present in part of a unique beta-
hairpin loop was also identified. A single 
mutation (L419M or M423V), located at the 
pyranoindole-binding site, resulted in an 8- to 
10-fold more resistant replicon, while a 
combination mutant (T19P, M71V, A338V, 
M423V, A442T) showed a 17-fold increase in 
drug resistance (36). 
 
Triggering and propagating an 
intracellular innate immune response is 
essential for control of HCV infections. RNase 
L is a host endoribonuclease and a pivotal 
component of innate immunity that cleaves 
viral and cellular RNA within single-stranded 
loops releasing small structured RNAs with 5'-
hydroxyl (5'-OH) and 3'-monophosphoryl (3'-
p) groups. The NS5B region of HCV RNA was 
cleaved by RNase L to release an svRNA that 
bound to RIG-I, displacing its repressor 
domain and stimulating its ATPase activity 
while signaling to the IFN-β gene in intact 
cells. All three of these RIG-I functions were 
dependent on the presence in svRNA of the 3'-
p. Furthermore, svRNA suppressed HCV 
replication in vitro through a mechanism 
involving IFN production and triggered a RIG-
I-dependent hepatic innate immune response 
in mice. RNase L and OAS (required for its 
activation) were both expressed in 
hepatocytes from HCV-infected patients, 
raising the possibility that the OAS/RNase L 
pathway might suppress HCV replication in 
vivo (37).  
 
Circulating auto-antibodies targeting 
conformational antigens on cytochrome 
P4502E1 (CYP2E1) are detectable in patients 
with chronic hepatitis C (CHC). The CYP2E1 is 
associated with more severe necro-
inflammation and might contribute to hepatic 
injury. The CYP2E1(324-346) peptide showed 
good homology with two sequences 
(NS5B(438-449) and NS5B(456-465)) within 
the NS5B protein of hepatitis C virus (HCV) 
[38]. However, in HCV 1a, variations were 
found at aa 440, 459, 461, and 464. 
 
The epitopes of eight mAbs are localized 
in the middle region (amino acid 240-263) of 
NS5B protein. On the other hand, the epitopes 
of two mAbs are mapped to amino acids 67-88 
at the N-terminus of NS5B protein. NS5B 
contains a B-cell epitope located between 
amino acid residues 67 and 88. Binding of this 
epitope with an antibody interferes with the 
enzymatic function of NS5B (39). Variations 
were found at aa 68, 248, 251, 252, 254, and 
262 in HCV 1a NS5B. 
 
The nucleotide sequence diversity 
present among hepatitis C virus (HCV) isolates 
allows rapid adjustment to exterior forces 
including host immunity and drug therapy. 
This viral response reflects a combination of a 
high rate of replication together with an error-
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prone RNA-dependent RNA polymerase, 
providing for the selection and proliferation of 
the viruses with the highest fitness. Signatures 
of HCV 1a NS5B were found abundant. The 
amino acid variations found in the present 
report need further study. In addition, it is 
possible that the establishment of a new 
scoring system consisting of molecular 
information may be a useful marker to predict 
therapy sensitivity for HCV. 
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